Gilead’s Trodelvy gets EC approval to treat triple-negative breast cancer
The EC marketing authorisation was based on results from the Phase 3 ASCENT study of Trodelvy in people…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
24 Nov 21
The EC marketing authorisation was based on results from the Phase 3 ASCENT study of Trodelvy in people…
23 Nov 21
The new 19,000m2 R&D facility that represents £1bn investment will feature the most advanced robotics, high-throughput screening and…
23 Nov 21
Arrowhead will receive $120m in upfront payment for the Phase 1/2 NASH programme, along with potential milestone payments…
22 Nov 21
Gavreto is a once-daily, oral precision medicine that works by selectively targeting rearranged during transfection (RET) alterations, including…
22 Nov 21
Voxzogo is the first treatment for achondroplasia, which is the most common form of disproportionate short stature, said…
19 Nov 21
Under the agreement, Pfizer will supply 10 million courses of the investigational Covid-19 drug to the US government,…
18 Nov 21
The regulatory approval is supported by data from Phase 3 KEEPsAKE-1 and KEEPsAKE-2 studies, evaluating Skyrizi in psoriatic…
18 Nov 21
GSK will supply the doses by 17 December 2021, and the US government holds an option to buy…
17 Nov 21
According to the company, Paxlovid would be the first 3CL protease inhibitor to be used as an oral…
17 Nov 21
The licenses Roche received under the collaboration will be returned to Atea, which will conduct clinical development and…